# Multimodality imaging of a rare case of apical hypertrophic cardiomyopathy with endomyocardial fibrosis and myocardial calcification: case report and literature review

**Authors:** Yuting Yi, Shuai Wang, Daoquan Peng

PMC · DOI: 10.3389/fcvm.2026.1774080 · Frontiers in Cardiovascular Medicine · 2026-02-18

## TL;DR

A rare case of apical hypertrophic cardiomyopathy with fibrosis and calcification is described, emphasizing the importance of multimodal imaging to avoid misdiagnosis as cancer.

## Contribution

This case highlights the rare coexistence of apical HCM with EMF and MC, and the potential for FDG-PET to mislead as malignancy.

## Key findings

- Multimodality imaging revealed apical hypertrophy, cavity obliteration, fibrosis, and calcification.
- FDG-PET showed intense apical uptake, initially suggesting malignancy but later attributed to HCM.
- Genetic testing identified a pathogenic MYH7 variant in the patient.

## Abstract

Apical hypertrophic cardiomyopathy (ApHCM) complicated by endomyocardial fibrosis (EMF) and myocardial calcification (MC) is an extremely rare clinical entity. This report describes a 54-year-old woman with exertional dyspnea and edema. Multimodality imaging revealed apical hypertrophy with cavity obliteration, endocardial fibrosis, and calcification. Notably, 18F-FDG PET-CT showed intense apical uptake, initially raising suspicion for malignancy. This finding underscores the importance of recognizing that increased FDG uptake can occur in ApHCM to avoid false-positive oncologic interpretations. The diagnosis was confirmed by endomyocardial biopsy—consistent with hypertrophic cardiomyopathy—and genetic testing, which identified a pathogenic MYH7 variant (c.4145G>A, p.R1382Q). A systematic literature review identified 13 reported cases of ApHCM with calcification. All exhibited apical hypertrophy and calcification; most (10/13) had concurrent endomyocardial fibrosis. Genetic testing was performed in 7 cases, with positive results in only 4, highlighting the genetic heterogeneity of this phenotype. This case underscores the value of integrated multimodality imaging in delineating complex structural abnormalities, characterizing calcification, and differentiating this condition from malignancies. Accurate diagnosis requires a combination of clinical presentation, advanced imaging, histopathology, and genetic analysis to guide appropriate management and avoid misdiagnosis.

## Linked entities

- **Genes:** MYH7 (myosin heavy chain 7) [NCBI Gene 4625]
- **Diseases:** endomyocardial fibrosis (MONDO:0006746)

## Full-text entities

- **Genes:** MYH7 (myosin heavy chain 7) [NCBI Gene 4625] {aka CMD1S, CMH1, CMYO7A, CMYO7B, CMYP7A, CMYP7B}, TMPO (thymopoietin) [NCBI Gene 7112] {aka CMD1T, LAP2, LEMD4, PRO0868, TP}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GATA6 (GATA binding protein 6) [NCBI Gene 2627], PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, MYBPC3 (myosin binding protein C3) [NCBI Gene 4607] {aka CMD1MM, CMH4, FHC, LVNC10, MYBP-C, cMyBP-C}
- **Diseases:** CMR (MESH:D006331), Hypertrophic cardiomyopathy (MESH:D002312), abdominal distention (MESH:D000007), atherosclerotic infarction (MESH:D007238), heart failure (MESH:D006333), TIA (MESH:D002546), mediastinal (MESH:D008480), embolic events (MESH:D004617), cardiac amyloidosis (MESH:D000686), EMF (MESH:D004719), radiation injury (MESH:D011832), cognitive impairment (MESH:D003072), Cardiac tumors (MESH:D006338), necrotic (MESH:D009336), calcified (MESH:D018333), malaria (MESH:D008288), ventricular hypertrophy (MESH:D024741), akinetic (MESH:D018476), ANA (MESH:D007153), hypertensive heart disease (MESH:D006973), LV thrombus (MESH:D013927), EFE (MESH:D004695), cerebral infarcts (MESH:D002544), chronic renal failure (MESH:D007676), ischemic injury (MESH:D017202), atrial fibrillation (MESH:D001281), Cardiac sarcoidosis (MESH:D012507), Apical hypertrophy (MESH:D006984), CKD (MESH:D012080), myocardial infarction (MESH:D009203), hyperthyroidism (MESH:D006980), myocarditis (MESH:D009205), cardiomyopathy (MESH:D009202), hypokinetic (MESH:D004401), obesity (MESH:D009765), intra-myocardial lesions (MESH:D009059), structural (MESH:D020914), gait disturbance (MESH:D020233), ventricular dilation or aneurysm (MESH:C566255), lymphadenopathy (MESH:D008206), LV myocardial calcification (MESH:D018487), mass (MESH:C536030), coronary stenosis (MESH:D023921), thalassemia (MESH:D013789), ApHCM (MESH:D000092183), metabolic hyperactivity (MESH:D008659), dystrophic (MESH:D020388), rhythm (MESH:D021081), endocardial ischemia (MESH:D007511), fibrosis (MESH:D005355), Apical (MESH:D010485), inflammation (MESH:D007249), respiratory tract infection (MESH:D012141), atrophy (MESH:D001284), atrophic (MESH:D020966), eosinophilia (MESH:D004802), DM (MESH:D009223), edema (MESH:D004487), Metastatic calcification (MESH:D000092182), malignancies (MESH:D009369)
- **Chemicals:** Rivaroxaban (MESH:D000069552), steroids (MESH:D013256), gadolinium (MESH:D005682), calcium (MESH:D002118), glucose (MESH:D005947), eosin (MESH:D004801), metoprolol (MESH:D008790), Hematoxylin (MESH:D006416), H&amp;E (MESH:D006371), lipofuscin (MESH:D008062), MC (-), fatty acid (MESH:D005227), 18F-FDG (MESH:D019788), metformin (MESH:D008687), phosphate (MESH:D010710), phosphorus (MESH:D010758), tolvaptan (MESH:D000077602), torasemide (MESH:D000077786)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.4145G>A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956803/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956803/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956803/full.md

---
Source: https://tomesphere.com/paper/PMC12956803